Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2003 2
2005 1
2007 1
2012 1
2013 1
2014 2
2015 1
2016 1
2017 2
2018 1
2019 3
2020 11
2021 7
2022 3
2023 3
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Poliprotect vs Omeprazole in the Relief of Heartburn, Epigastric Pain, and Burning in Patients Without Erosive Esophagitis and Gastroduodenal Lesions: A Randomized, Controlled Trial.
Corazziari ES, Gasbarrini A, D'Alba L, D'Ovidio V, Riggio O, Passaretti S, Annibale B, Cicala M, Repici A, Bassotti G, Ciacci C, Di Sabatino A, Neri M, Bragazzi MC, Ribichini E, Radocchia G, Iovino P, Marazzato M, Schippa S, Badiali D. Corazziari ES, et al. Am J Gastroenterol. 2023 Nov 1;118(11):2014-2024. doi: 10.14309/ajg.0000000000002360. Epub 2023 Jun 13. Am J Gastroenterol. 2023. PMID: 37307528 Free PMC article. Clinical Trial.
Development and Validation of a Scoring System to Predict Response to Obeticholic Acid in Primary Biliary Cholangitis.
De Vincentis A, Ampuero J, Terracciani F, D'Amato D, Gerussi A, Cristoferi L, Cazzagon N, Bonaiuto E, Floreani A, Calvaruso V, Cadamuro L, Degasperi E, Morgando A, Vanni E, Lleo A, Colapietro F, Alvaro D, Castellaneta A, Labanca S, Viganò M, Distefano M, Pace Palitti V, Ricci C, De Matthaeis N, Marzioni M, Gómez-Dominguez E, Montero JL, Molina E, Garcia-Buey L, Casado M, Berenguer M, Conde I, Simon MA, Fuentes J, Costa-Moreira P, Macedo G, Jorquera F, Morillas RM, Presa J, Sousa JM, Gomes D, Santos L, Olveira A, Hernandez-Guerra M, Aburruza L, Santos A, Carvalho A, Uriz J, Gutierrez ML, Perez E, Chessa L, Pellicelli A, Marignani M, Muratori L, Niro GA, Brunetto M, Ponziani FR, Pompili M, Marra F, Galli A, Mussetto A, Alagna G, Simone L, Bertino G, Rosina F, Cozzolongo R, Russello M, Baiocchi L, Saitta C, Terreni N, Zolfino T, Rigamonti C, Vigano R, Cuccorese G, Pozzoni P, Pedone C, Grasso S, Picardi A, Invernizzi P, Sacco R, Izzi A, Fernandez-Rodriguez C, Vespasiani-Gentilucci U, Carbone M; RECAPITULATE Investigators. De Vincentis A, et al. Clin Gastroenterol Hepatol. 2024 Oct;22(10):2062-2074.e11. doi: 10.1016/j.cgh.2024.05.008. Epub 2024 May 22. Clin Gastroenterol Hepatol. 2024. PMID: 38782175
Postlung transplant survival is equivalent regardless of cytomegalovirus match status.
Russo MJ, Sternberg DI, Hong KN, Sorabella RA, Moskowitz AJ, Gelijns AC, Wilt JR, D'Ovidio F, Kawut SM, Arcasoy SM, Sonett JR. Russo MJ, et al. Ann Thorac Surg. 2007 Oct;84(4):1129-34; discussion 1134-5. doi: 10.1016/j.athoracsur.2007.05.037. Ann Thorac Surg. 2007. PMID: 17888958
Based on pretransplant CMV serologic status (+ or -) of recipients (R) and donors (D), posttransplant survival was compared among three groups: D+ /R-, D+/- /R+, and D- /R-. ...During the three periods, survival improved significantly in D+ /R- …
Based on pretransplant CMV serologic status (+ or -) of recipients (R) and donors (D), posttransplant survival was compared among thr …
Donor surfactant protein A2 polymorphism and lung transplant survival.
D'Ovidio F, Floros J, Aramini B, Lederer D, DiAngelo SL, Arcasoy S, Sonett JR, Robbins H, Shah L, Costa J, Urso A. D'Ovidio F, et al. Eur Respir J. 2020 Mar 5;55(3):1900618. doi: 10.1183/13993003.00618-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 31831583 Free article.
Amyotrophic lateral sclerosis regional progression intervals change according to time of involvement of different body regions.
Manera U, D'Ovidio F, Cabras S, Torrieri MC, Canosa A, Vasta R, Palumbo F, Grassano M, De Marchi F, Mazzini L, Mora G, Moglia C, Calvo A, Chiò A. Manera U, et al. Eur J Neurol. 2023 Apr;30(4):872-880. doi: 10.1111/ene.15674. Epub 2023 Jan 23. Eur J Neurol. 2023. PMID: 36617536 Free article.
We calculated the regional progression intervals (RPIs) between initial involvement and severe functional impairment using the ALS Functional Rating Scale revised (ALSFRS-r) subscores for the bulbar, upper limb, lower limb and respiratory/thoracic regions. Time-to-event an …
We calculated the regional progression intervals (RPIs) between initial involvement and severe functional impairment using the ALS Functiona …
Causal associations of genetic factors with clinical progression in amyotrophic lateral sclerosis.
Ahangaran M, Chiò A, D'Ovidio F, Manera U, Vasta R, Canosa A, Moglia C, Calvo A, Minaei-Bidgoli B, Jahed-Motlagh MR. Ahangaran M, et al. Comput Methods Programs Biomed. 2022 Apr;216:106681. doi: 10.1016/j.cmpb.2022.106681. Epub 2022 Feb 3. Comput Methods Programs Biomed. 2022. PMID: 35151113
Our findings revealed that causal relationships between ALSFRS-R items associated with bulbar regions have the strongest association with genetic factors, especially C9ORF72; and other three genes have the greatest contribution to the respiratory ALSFRS-R items with …
Our findings revealed that causal relationships between ALSFRS-R items associated with bulbar regions have the strongest association …
38 results